Sclerosing cholangitis

Current Opinion in Gastroenterology

Volumn 17, Issue 5, 2001, Pages 458-462

  Martins, Eduardo B ^a,c   Chapman, Roger W ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BUDESONIDE; CARDIOLIPIN ANTIBODY; CATHEPSIN G; CLADRIBINE; ELASTASE; PENTOXIFYLLINE; URSODEOXYCHOLIC ACID;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; BACTERIAL GENE; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE SEQUENCE; HELICOBACTER; HUMAN; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PROGNOSIS; RADIODIAGNOSIS; REVIEW; SCLEROSING CHOLANGITIS; TREATMENT FAILURE;

EID: 0034859531     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200109000-00010     Document Type: Review

References (41)

1. The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: No associations with disease susceptibility/resistance
2. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins
3. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines
4. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases
5. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: Prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease
6. Serum autoantibodies in patients with primary sclerosing cholangitis
7. A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF-alpha production and autoantibodies
8. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis
9. A revised natural history model for primary sclerosing cholangitis
10. Neonatal sclerosing cholangitis associated with autoimmune phenomena
11. Immunological similarities between primary sclerosing cholangitis and chronic sclerosing sialadenitis: Report of the overlapping of these two autoimmune diseases
12. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis
13. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: A followup study over 14 years
14. Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases
15. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis
16. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system
17. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: To score or not to score?
18. Chronic inflammatory bowel disease and cancer
19. PSC in UC: Is it or is it not a risk factor for the development of neoplasia?
20. Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma
21. Simultaneous occurrence of focal nodular hyperplasia and primary sclerosing cholangitis in a young female
22. A case of segmental primary sclerosing cholangitis
23. Autoimmune hepatobiliary disease in trisomy 21
24. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis
25. Radiologic manifestations of sclerosing cholangitis with emphasis on MR cholangiopancreatography
26. Primary sclerosing cholangitis: Evaluation with MR cholangiography - A case-control study
27. Magnetic resonance cholangiography in patients with biliary disease: Its role in primary sclerosing cholangitis
28. Treatment options for other hepatic malignancies
29. Early detection and treatment of cholangiocarcinoma
30. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis
31. Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis?
32. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development
33. Ursodeoxycholic acid therapy in hepatobiliary disease
34. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children
35. Oral budesonide in the treatment of primary sclerosing cholangitis
36. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study
37. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis
38. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis
39. Liver transplantation for primary sclerosing cholangitis
40. Liver transplantation for primary sclerosing cholangitis: A single-center experience
41. Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child-Pugh score